Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
18.62
+0.85 (4.78%)
Nov 5, 2024, 4:00 PM EST - Market closed

Entrada Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Revenue
215.23129.01----
Cost of Revenue
99.8899.8866.61---
Gross Profit
115.3529.13-66.61---
Selling, General & Admin
37.2632.2930.6415.25.573.61
Research & Development
20.31--35.9321.18.22
Operating Expenses
57.5732.2930.6451.1326.6711.82
Operating Income
57.78-3.16-97.25-51.13-26.67-11.82
Interest & Investment Income
18.6415.222.630.040.160.45
Other Non Operating Income (Expenses)
-----6.27
EBT Excluding Unusual Items
76.4212.06-94.62-51.08-26.5-5.1
Gain (Loss) on Sale of Assets
----0.07-0.02-
Pretax Income
76.4212.06-94.62-51.16-26.52-5.1
Income Tax Expense
21.4718.74----
Net Income
54.95-6.69-94.62-51.16-26.52-5.1
Net Income to Common
54.95-6.69-94.62-51.16-26.52-5.1
Shares Outstanding (Basic)
353331611
Shares Outstanding (Diluted)
363331611
Shares Change (YoY)
9.14%5.61%399.27%467.09%18.45%-
EPS (Basic)
1.55-0.20-3.02-8.16-24.00-5.47
EPS (Diluted)
1.55-0.20-3.02-8.16-24.00-5.47
Free Cash Flow
-17.46134.19-96.67-55.44-27.89-11.43
Free Cash Flow Per Share
-0.494.06-3.09-8.85-25.23-12.25
Gross Margin
53.59%22.58%----
Operating Margin
26.85%-2.45%----
Profit Margin
25.53%-5.18%----
Free Cash Flow Margin
-8.11%104.01%----
EBITDA
61.3-0.32-95.35-50.01-26.34-11.72
EBITDA Margin
28.48%-0.25%----
D&A For EBITDA
3.522.841.91.120.330.1
EBIT
57.78-3.16-97.25-51.13-26.67-11.82
EBIT Margin
26.85%-2.45%----
Effective Tax Rate
28.09%155.45%----
Source: S&P Capital IQ. Standard template. Financial Sources.